Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term administration &. Found 7 abstracts

Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochemical pharmacology. 2010 Sep;80(5):762-70.   PMCID: PMC2897922
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys. 2009 May;74(1):55-9.   PMCID: PMC2933375
Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009 May;115(9):1859-66.
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7.   PMCID: PMC 2741166
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term administration &

administration & dosage drug therapy therapeutic use Middle Aged Female Antineoplastic Combined Chemotherapy Protocols analogs & Male Monoclonal Antibodies pathology Aged derivatives Peritoneal Neoplasms adverse effects Adult Epidermal Growth Factor Receptor pharmacokinetics Neoplasm Staging Paclitaxel metabolism Carboplatin Antineoplastic Agents Disease-Free Survival Adenocarcinoma radiotherapy Deoxycytidine Ovarian Neoplasms Young Adult Topotecan chemically induced Drug Administration Schedule Angiogenesis Inhibitors Proteomics genetics Prospective Studies Polyethylene Glycols Squamous Cell Carcinoma Maximum Tolerated Dose Drug Dose-Response Relationship Iodine Radioisotopes Treatment Outcome Radioimmunotherapy Drug Carriers Interferon-alpha Analysis of Variance Combined Modality Therapy Neoplasm Metastasis Rectal Neoplasms methods Brain Neoplasms Neoplasms Bronchiolo-Alveolar Adenocarcinoma Neoadjuvant Therapy Acneiform Eruptions Renal Cell Carcinoma Retrospective Studies Kidney Neoplasms Prognosis Fluorouracil Intravenous Infusions Liposomes blood Fluorodeoxyglucose F18 Disease Progression Doxorubicin Multivariate Analysis Drug Delivery Systems Mitomycin Biological Tumor Markers diagnostic use secondary radionuclide imaging Local Neoplasm Recurrence Recurrence Survival Rate mortality Nonparametric Statistics Non-Small-Cell Lung Carcinoma immunology Radiopharmaceuticals Adjuvant Radiotherapy Outcome Assessment (Health Care) Glioblastoma Positron-Emission Tomography Proportional Hazards Models Alkylating Antineoplastic Agents Dacarbazine Kaplan-Meiers Estimate Micelles Lung Neoplasms
Last updated on Wednesday, February 05, 2020